Israel's Nano-X Imaging misses Q1 revenue estimates

Nano-X Imaging

25/06/2026 13:11

Overview
Israel-based medical imaging firm's Q1 revenue rose yr/yr but missed analyst expectations
Adjusted net loss for Q1 narrowed, coming in less than analyst expectations
Company says it no longer expects to achieve its 2026 revenue target due to timing uncertainties

Outlook
Nano-X will not provide annual revenue guidance going forward
Company says commercialization pace depends on market adoption, regulatory approvals and partner performance

Result Drivers
TELERADIOLOGY SERVICES - Revenue growth was mainly driven by increased teleradiology services, with higher customer retention, increased rates, and more weekday scan volumes
SYSTEM DEPLOYMENTS - Increased scans and utilization of deployed Nanox.ARC systems, including commercial use at a RadNet site, contributed to revenue and operational progress

Company press release: ID:nGNXbs7zk3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$4.30 mln
$4.53 mln (3 Analysts)
Q1 EPS
 
-$0.20
 
Q1 Adjusted Net Income
Beat
-$11.10 mln
-$13.51 mln (3 Analysts)
Q1 Net Income
 
-$14.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Nano-X Imaging Ltd is $7.00, about 345.9% above its June 24 closing price of $1.57

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)